CXCR3 blockade inhibits T-cell migration into the CNS during EAE and prevents development of adoptively transferred, but not actively induced, disease.
Sporici
Romeo
R
Departments of Pediatrics and Microbiology & Immunology, Dalhousie Inflammation Group, Dalhousie University, Halifax, NS, Canada.
Issekutz
Thomas B
TB
D019264:Adoptive Transfer / Q000379:methods; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002465:Cell Movement / Q000276:immunology*; D002490:Central Nervous System / Q000276:immunology*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000628:therapy; D005434:Flow Cytometry; D006651:Histocytochemistry; D007371:Interferon-gamma / Q000235:genetics / Q000276:immunology; D020381:Interleukin-17 / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000737:chemistry / Q000235:genetics; D051381:Rats; D011917:Rats, Inbred Lew; D054367:Receptors, CXCR3 / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D020381:Interleukin-17; D012333:RNA, Messenger; D054367:Receptors, CXCR3; D007371:Interferon-gamma